START Midwest‘s Nehal Lakhani, MD, PhD, and Manish Sharma, MD, were granted oral presentations at the European Society for Medical Oncology (ESMO)‘s Virtual 2020 Congress. The physicians’ presentations were two of the four “Investigational Immunotherapy” presentations selected to be shared.
Dr. Lakhani’s presentation titled “Phase 1 studies of Sym021, an anti-PD-1 antibody, alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)” took place Sunday, Sept. 20. Dr. Sharma’s presentation titled “A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD019, an Investigational Bispecific PD-1 × CTLA-4 DART® Molecule in Patients with Advanced Solid Tumors” also took place on the same day.
ESMO is a professional organization comprised of more than 25,000 members dedicated to the study of medical oncology. The ESMO Virtual Congress 2020 consists of new developments in the field of cancer care.
START Midwest, located at CHCWM’s East facility, is part of START’s global network of Phase I clinical research sites. It is the largest Phase I oncology drug development program in Michigan and one of the largest in the Midwest. It offers cancer patients access to cutting-edge clinical trial drugs, including immunotherapy and targeted therapy options.
Becky Downing, Social Media & Marketing Specialist